Aryx Therapeutics I Stock Net Income
| ARYX Stock | USD 0.0005 0.00 0.00% |
Aryx Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Aryx Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Aryx Therapeutics' valuation are provided below:Aryx Therapeutics I does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Aryx |
Aryx Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Aryx Therapeutics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Aryx Therapeutics.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Aryx Therapeutics on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Aryx Therapeutics I or generate 0.0% return on investment in Aryx Therapeutics over 90 days. ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets More
Aryx Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Aryx Therapeutics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Aryx Therapeutics I upside and downside potential and time the market with a certain degree of confidence.
Aryx Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aryx Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Aryx Therapeutics' standard deviation. In reality, there are many statistical measures that can use Aryx Therapeutics historical prices to predict the future Aryx Therapeutics' volatility.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Aryx Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Aryx Therapeutics Backtested Returns
We have found three technical indicators for Aryx Therapeutics I, which you can use to evaluate the volatility of the firm. The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Aryx Therapeutics are completely uncorrelated.
Auto-correlation | 0.00 |
No correlation between past and present
Aryx Therapeutics I has no correlation between past and present. Overlapping area represents the amount of predictability between Aryx Therapeutics time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Aryx Therapeutics price movement. The serial correlation of 0.0 indicates that just 0.0% of current Aryx Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Aryx Therapeutics I reported net income of (33.17 Million). This is 109.72% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 105.81% higher than that of the company.
Aryx Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aryx Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aryx Therapeutics could also be used in its relative valuation, which is a method of valuing Aryx Therapeutics by comparing valuation metrics of similar companies.Aryx Therapeutics is currently under evaluation in net income category among its peers.
Aryx Fundamentals
| Return On Asset | -0.75 | |||
| Current Valuation | 237.58 K | |||
| Shares Outstanding | 33.46 M | |||
| Shares Owned By Institutions | 0.14 % | |||
| Number Of Shares Shorted | 89.05 K | |||
| Price To Book | 37.83 X | |||
| EBITDA | (14.18 M) | |||
| Net Income | (33.17 M) | |||
| Cash And Equivalents | 2.95 M | |||
| Cash Per Share | 0.09 X | |||
| Debt To Equity | (5.11) % | |||
| Current Ratio | 0.47 X | |||
| Book Value Per Share | (0.23) X | |||
| Cash Flow From Operations | (34.97 M) | |||
| Short Ratio | 0.79 X | |||
| Earnings Per Share | (0.59) X | |||
| Target Price | 1.5 | |||
| Number Of Employees | 56 | |||
| Beta | 0.0896 | |||
| Market Capitalization | 237.58 K | |||
| Total Asset | 12.41 M | |||
| Retained Earnings | (187.11 M) | |||
| Working Capital | 126 K | |||
| Current Asset | 8.62 M | |||
| Current Liabilities | 8.49 M | |||
| Z Score | -24.3 | |||
| Net Asset | 12.41 M |
About Aryx Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aryx Therapeutics I's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aryx Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aryx Therapeutics I based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Aryx Pink Sheet Analysis
When running Aryx Therapeutics' price analysis, check to measure Aryx Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aryx Therapeutics is operating at the current time. Most of Aryx Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aryx Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aryx Therapeutics' price. Additionally, you may evaluate how the addition of Aryx Therapeutics to your portfolios can decrease your overall portfolio volatility.